Companion Diagnostics Market Research Report Information by Product & Service (Assays, Kits, & Reagents and Software & Services), by Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), In Situ Hybridization (ISH), Immunohistochemistry (IHC), and Others), by Indication (Cancer [Lung Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Melanoma, and Others], Neurological Diseases, Infectious Diseases, Cardiovascular Diseases, and Others), by End User (Pharmaceutical & Biopharmaceutical Companies, Contract Resea

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY

2.2 RESEARCH OBJECTIVE

2.3 LIST OF ASSUMPTIONS

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA MINING

3.3 SECONDARY RESEARCH

3.4 PRIMARY RESEARCH

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 RISING PREFERENCE FOR PERSONALIZED MEDICINE

4.2.2 INCREASING COLLABORATION AMONG COMPANIES AND DRUG-DIAGNOSTIC CO-DEVELOPMENT

4.2.3 INCREASING PRODUCT APPROVAL BY MAJOR PLAYERS

4.3 RESTRAINTS

4.3.1 LACK OF REIMBURSEMENT IN DEVELOPING REGIONS

4.3.2 LIMITED ADOPTION OF CDX AND PRESENCE OF ALTERNATIVE THERAPIES

4.4 OPPORTUNITIES

4.4.1 EXPANSION INTO NEWER INDICATION AREAS

5 MARKET FACTOR ANALYSIS

5.1 SUPPLY CHAIN ANALYSIS

5.1.1 R&D AND DESIGNING

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION

5.1.4 MARKETING & SALES

5.1.5 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF CORONAVIRUS (COVID)-19

6 GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

6.1 OVERVIEW

6.2 ASSAYS, KITS, & REAGENTS

6.3 SOFTWARE & SERVICES

7 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

7.1 OVERVIEW

7.2 POLYMERASE CHAIN REACTION (PCR)

7.3 NEXT-GENERATION SEQUENCING (NGS)

7.4 IN SITU HYBRIDIZATION (ISH)

7.5 IMMUNOHISTOCHEMISTRY (IHC)

7.6 OTHERS

8 GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION

8.1 OVERVIEW

8.2 CANCER

8.2.1 LUNG CANCER

8.2.2 BREAST CANCER

8.2.3 COLORECTAL CANCER

8.2.4 GASTRIC CANCER

8.2.5 MELANOMA

8.2.6 OTHERS

8.3 NEUROLOGICAL DISEASES

8.4 INFECTIOUS DISEASES

8.5 CARDIOVASCULAR DISEASES

8.6 OTHERS

9 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER

9.1 OVERVIEW

9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES

9.3 CONTRACT RESEARCH ORGANIZATIONS

9.4 LABORATORIES

9.5 OTHERS

10 GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION

10.1 OVERVIEW

10.2 AMERICAS

10.2.1 NORTH AMERICA

10.2.1.1 US

10.2.1.2 CANADA

10.2.2 LATIN AMERICA

10.3 EUROPE

10.3.1 WESTERN EUROPE

10.3.1.1 GERMANY

10.3.1.2 FRANCE

10.3.1.3 UK

10.3.1.4 ITALY

10.3.1.5 SPAIN

10.3.1.6 REST OF WESTERN EUROPE

10.3.2 EASTERN EUROPE

10.4 ASIA-PACIFIC

10.4.1 CHINA

10.4.2 JAPAN

10.4.3 INDIA

10.4.4 AUSTRALIA

10.4.5 SOUTH KOREA

10.4.6 REST OF ASIA-PACIFIC

10.5 MIDDLE EAST & AFRICA

10.5.1 MIDDLE EAST

10.5.2 AFRICA

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW

11.2 COMPETITIVE BENCHMARKING

11.3 MAJOR GROWTH STRATEGY IN COMPANION DIAGNOSTIC MARKET

11.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE COMPANION DIAGNOSTIC MARKET

11.5 KEY DEVELOPMENT ANALYSIS

11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

11.6.1 PRODUCT APPROVALS AND PRODUCT LAUNCHES

11.6.2 PARTNERSHIP/COLLABORATION

11.6.3 EXPANSIONS/AGREEMENT

11.6.4 MERGERS & ACQUISITIONS

11.7 MAJOR PLAYERS SALES ANALYSIS

11.7.1 SALES & OPERATING INCOME

11.8 MAJOR PLAYERS R&D ANALYSIS

12 COMPANY PROFILES

12.1 F. HOFFMANN-LA ROCHE LTD

12.1.1 COMPANY OVERVIEW

12.1.2 FINANCIAL OVERVIEW

12.1.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED

12.1.4 KEY DEVELOPMENTS

12.1.5 SWOT ANALYSIS

12.1.6 KEY STRATEGIES

12.2 THERMO FISHER SCIENTIFIC INC.

12.2.1 COMPANY OVERVIEW

12.2.2 FINANCIAL OVERVIEW

12.2.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED

12.2.4 KEY DEVELOPMENTS

12.2.5 SWOT ANALYSIS

12.2.6 KEY STRATEGIES

12.3 AGILENT TECHNOLOGIES, INC.

12.3.1 COMPANY OVERVIEW

12.3.2 FINANCIAL OVERVIEW

12.3.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED

12.3.4 KEY DEVELOPMENTS

12.3.5 SWOT ANALYSIS

12.3.6 KEY STRATEGIES

12.4 QIAGEN

12.4.1 COMPANY OVERVIEW

12.4.2 FINANCIAL OVERVIEW

12.4.3 PRODUCTS/SERVICES OFFERED

12.4.4 KEY DEVELOPMENTS

12.4.5 SWOT ANALYSIS

12.4.6 KEY STRATEGIES

12.5 ABBOTT

12.5.1 COMPANY OVERVIEW

12.5.2 FINANCIAL OVERVIEW

12.5.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED

12.5.4 KEY DEVELOPMENTS

12.5.5 KEY STRATEGIES

12.6 BIOMÉRIEUX SA

12.6.1 COMPANY OVERVIEW

12.6.2 FINANCIAL OVERVIEW

12.6.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED

12.6.4 KEY DEVELOPMENTS

12.6.5 KEY STRATEGIES

12.7 LEICA BIOSYSTEMS NUSSLOCH GMBH

12.7.1 COMPANY OVERVIEW

12.7.2 FINANCIAL OVERVIEW

12.7.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED

12.7.4 KEY DEVELOPMENTS

12.7.5 KEY STRATEGIES

12.8 ILLUMINA, INC.

12.8.1 COMPANY OVERVIEW

12.8.2 FINANCIAL OVERVIEW

12.8.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED

12.8.4 KEY DEVELOPMENTS

12.8.5 KEY STRATEGIES

12.9 MYRIAD GENETICS, INC

12.9.1 COMPANY OVERVIEW

12.9.2 FINANCIAL OVERVIEW

12.9.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED

12.9.4 KEY DEVELOPMENTS

12.9.5 SWOT ANALYSIS

12.9.6 KEY STRATEGIES

12.10 ARCHERDX, INC.

12.10.1 COMPANY OVERVIEW

12.10.2 FINANCIAL OVERVIEW

12.10.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED

12.10.4 KEY DEVELOPMENTS

12.10.5 KEY STRATEGIES

12.11 FOUNDATION MEDICINE, INC.

12.11.1 COMPANY OVERVIEW

12.11.2 FINANCIAL OVERVIEW

12.11.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED

12.11.4 KEY DEVELOPMENTS

12.11.5 KEY STRATEGIES

12.12 NG BIOTECH

12.12.1 COMPANY OVERVIEW

12.12.2 FINANCIAL OVERVIEW

12.12.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED

12.12.4 KEY DEVELOPMENTS

12.12.5 KEY STRATEGIES

12.13 ICON PLC

12.13.1 COMPANY OVERVIEW

12.13.2 FINANCIAL OVERVIEW

12.13.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED

12.13.4 KEY DEVELOPMENTS

12.13.5 KEY STRATEGIES

12.14 INVIVOSCRIBE, INC.

12.14.1 COMPANY OVERVIEW

12.14.2 FINANCIAL OVERVIEW

12.14.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED

12.14.4 KEY DEVELOPMENTS

12.14.5 KEY STRATEGIES

12.15 ABNOVA CORPORATION

12.15.1 COMPANY OVERVIEW

12.15.2 FINANCIAL OVERVIEW

12.15.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED

12.15.4 KEY DEVELOPMENTS

12.15.5 KEY STRATEGIES

12.16 GUARDANT HEALTH

12.16.1 COMPANY OVERVIEW

12.16.2 FINANCIAL OVERVIEW

12.16.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED

12.16.4 KEY DEVELOPMENTS

12.16.5 KEY STRATEGIES

13 APPENDIX

13.1 REFERENCES

13.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)

TABLE 3 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR ASSAYS, KITS, & REAGENTS, BY REGION, 2018-2030 (USD MILLION)

TABLE 4 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)

TABLE 5 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)

TABLE 6 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2030 (USD MILLION)

TABLE 7 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)

TABLE 8 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR IN SITU HYBRIDIZATION (ISH), BY REGION, 2018-2030 (USD MILLION)

TABLE 9 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR IMMUNOHISTOCHEMISTRY (IHC), BY REGION, 2018-2030 (USD MILLION)

TABLE 10 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR OTHER TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)

TABLE 11 GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2030 (USD MILLION)

TABLE 12 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR CANCER, BY TYPE, 2018-2030 (USD MILLION)

TABLE 13 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR CANCER, BY REGION, 2018-2030 (USD MILLION)

TABLE 14 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)

TABLE 15 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)

TABLE 16 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)

TABLE 17 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR GASTRIC CANCER, BY REGION, 2018-2030 (USD MILLION)

TABLE 18 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR MELANOMA, BY REGION, 2018-2030 (USD MILLION)

TABLE 19 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR OTHER CANCERS, BY REGION, 2018-2030 (USD MILLION)

TABLE 20 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)

TABLE 21 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)

TABLE 22 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)

TABLE 23 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR OTHER DISEASES, BY REGION, 2018-2030 (USD MILLION)

TABLE 24 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 25 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)

TABLE 26 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)

TABLE 27 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR LABORATORIES, BY REGION, 2018-2030 (USD MILLION)

TABLE 28 GLOBAL COMPANION DIAGNOSTICS MARKET, FOR OTHER END USERS, BY REGION, 2018-2030 (USD MILLION)

TABLE 29 GLOBAL: COMPANION DIAGNOSTICS MARKET, BY REGION, 2018-2030 (USD MILLION)

TABLE 30 AMERICAS: COMPANION DIAGNOSTICS MARKET, BY REGION, 2018-2030 (USD MILLION)

TABLE 31 AMERICAS: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)

TABLE 32 AMERICAS: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)

TABLE 33 AMERICAS: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2030 (USD MILLION)

TABLE 34 AMERICAS: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018-2030 (USD MILLION)

TABLE 35 AMERICAS: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 36 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018-2030 (USD MILLION)

TABLE 37 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)

TABLE 38 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)

TABLE 39 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2030 (USD MILLION)

TABLE 40 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018-2030 (USD MILLION)

TABLE 41 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 42 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)

TABLE 43 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)

TABLE 44 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2030 (USD MILLION)

TABLE 45 US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018-2030 (USD MILLION)

TABLE 46 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 47 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)

TABLE 48 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)

TABLE 49 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2030 (USD MILLION)

TABLE 50 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018-2030 (USD MILLION)

TABLE 51 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 52 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)

TABLE 53 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)

TABLE 54 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2030 (USD MILLION)

TABLE 55 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018-2030 (USD MILLION)

TABLE 56 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 57 EUROPE: COMPANION DIAGNOSTICS MARKET, BY REGION, 2018-2030 (USD MILLION)

TABLE 58 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018–2030 (USD MILLION)

TABLE 59 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 60 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2030 (USD MILLION)

TABLE 61 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018–2030 (USD MILLION)

TABLE 62 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 63 WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018-2030 (USD MILLION)

TABLE 64 WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018–2030 (USD MILLION)

TABLE 65 WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 66 WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2030 (USD MILLION)

TABLE 67 WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018–2030 (USD MILLION)

TABLE 68 WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 69 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018–2030 (USD MILLION)

TABLE 70 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 71 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2030 (USD MILLION)

TABLE 72 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018–2030 (USD MILLION)

TABLE 73 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 74 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018–2030 (USD MILLION)

TABLE 75 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 76 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2030 (USD MILLION)

TABLE 77 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018–2030 (USD MILLION)

TABLE 78 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 79 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018–2030 (USD MILLION)

TABLE 80 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 81 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2030 (USD MILLION)

TABLE 82 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018–2030 (USD MILLION)

TABLE 83 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 84 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018–2030 (USD MILLION)

TABLE 85 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 86 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2030 (USD MILLION)

TABLE 87 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018–2030 (USD MILLION)

TABLE 88 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 89 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018–2030 (USD MILLION)

TABLE 90 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 91 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2030 (USD MILLION)

TABLE 92 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018–2030 (USD MILLION)

TABLE 93 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 94 REST OF WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018–2030 (USD MILLION)

TABLE 95 REST OF WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 96 REST OF WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2030 (USD MILLION)

TABLE 97 REST OF WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018–2030 (USD MILLION)

TABLE 98 REST OF WESTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 99 EASTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018–2030 (USD MILLION)

TABLE 100 EASTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 101 EASTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2030 (USD MILLION)

TABLE 102 EASTERN EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018–2030 (USD MILLION)

TABLE 103 EASTERN EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 104 ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018-2030 (USD MILLION)

TABLE 105 ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)

TABLE 106 ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)

TABLE 107 ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2030 (USD MILLION)

TABLE 108 ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018-2030 (USD MILLION)

TABLE 109 ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 110 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)

TABLE 111 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)

TABLE 112 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2030 (USD MILLION)

TABLE 113 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018-2030 (USD MILLION)

TABLE 114 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 115 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)

TABLE 116 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)

TABLE 117 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2030 (USD MILLION)

TABLE 118 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018-2030 (USD MILLION)

TABLE 119 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 120 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)

TABLE 121 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)

TABLE 122 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2030 (USD MILLION)

TABLE 123 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018-2030 (USD MILLION)

TABLE 124 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 125 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)

TABLE 126 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)

TABLE 127 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2030 (USD MILLION)

TABLE 128 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018-2030 (USD MILLION)

TABLE 129 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 130 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)

TABLE 131 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)

TABLE 132 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2030 (USD MILLION)

TABLE 133 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018-2030 (USD MILLION)

TABLE 134 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 135 REST OF ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)

TABLE 136 REST OF ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)

TABLE 137 REST OF ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018-2030 (USD MILLION)

TABLE 138 REST OF ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018-2030 (USD MILLION)

TABLE 139 REST OF ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018-2030 (USD MILLION)

TABLE 140 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 141 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018–2030 (USD MILLION)

TABLE 142 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 143 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2030 (USD MILLION)

TABLE 144 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018–2030 (USD MILLION)

TABLE 145 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 146 MIDDLE EAST: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018–2030 (USD MILLION)

TABLE 147 MIDDLE EAST: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 148 MIDDLE EAST: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2030 (USD MILLION)

TABLE 149 MIDDLE EAST: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018–2030 (USD MILLION)

TABLE 150 MIDDLE EAST: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 151 AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2018–2030 (USD MILLION)

TABLE 152 AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2030 (USD MILLION)

TABLE 153 AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2030 (USD MILLION)

TABLE 154 AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2018–2030 (USD MILLION)

TABLE 155 AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 156 MAJOR MANUFACTURERS IN THE COMPANION DIAGNOSTIC MARKET

TABLE 157 MOST ACTIVE PLAYER IN COMPANION DIAGNOSTIC MARKET

TABLE 158 PRODUCT APPROVALS AND PRODUCT LAUNCHES

TABLE 159 PARTNERSHIP/COLLABORATION

TABLE 160 EXPANSION/ AGREEMENT

TABLE 161 MERGERS & ACQUISITIONS

TABLE 162 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 163 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES /SOLUTIONS OFFERED

TABLE 164 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS

TABLE 165 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 166 AGILENT TECHNOLOGIES, INC.: KEY DEVELOPMENTS

TABLE 167 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 168 QIAGEN: KEY DEVELOPMENTS

TABLE 169 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 170 BIOMÉRIEUX SA: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 171 LEICA BIOSYSTEMS NUSSLOCH GMBH: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 172 LEICA BIOSYSTEMS NUSSLOCH GMBH: KEY DEVELOPMENTS

TABLE 173 ILLUMINA, INC: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 174 ILLUMINA, INC.: KEY DEVELOPMENTS

TABLE 175 MYRIAD GENETICS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 176 MYRIAD GENETICS, INC.: KEY DEVELOPMENTS

TABLE 177 ARCHERDX, INC: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 178 ARCHERDX, INC.: KEY DEVELOPMENTS

TABLE 179 FOUNDATION MEDICINE, INC: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 180 FOUNDATION MEDICINE, INC: KEY DEVELOPMENTS

TABLE 181 NG BIOTECH: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 182 ICON PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 183 ICON PLC.: KEY DEVELOPMENTS

TABLE 184 INVIVOSCRIBE, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 185 INVIVOSCRIBE, INC.: KEY DEVELOPMENTS

TABLE 186 ABNOVA CORPORATION: PRODUCTS/SERVICES OFFERED

TABLE 187 ABNOVA CORPORATION: KEY DEVELOPMENTS

TABLE 188 GUARDANT HEALTH: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 189 GUARDANT HEALTH: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS

FIGURE 2 GLOBAL COMPANION DIAGNOSTICS MARKET STRUCTURE

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES

FIGURE 4 MARKET DYNAMICS: GLOBAL COMPANION DIAGNOSTICS MARKET

FIGURE 5 DRIVERS: IMPACT ANALYSIS

FIGURE 6 RESTRAINTS: IMPACT ANALYSIS

FIGURE 7 SUPPLY CHAIN ANALYSIS: GLOBAL COMPANION DIAGNOSTICS MARKET

FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL COMPANION DIAGNOSTICS MARKET

FIGURE 9 GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, 2020 & 2030 (USD MILLION)

FIGURE 10 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 & 2030 (USD MILLION)

FIGURE 11 GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020 & 2030 (USD MILLION)

FIGURE 12 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER, 2020 & 2030 (USD MILLION)

FIGURE 13 GLOBAL COMPANION DIAGNOSTICS MARKET SHARE, BY REGION, 2020 & 2030 (USD MILLION)

FIGURE 14 AMERICAS: COMPANION DIAGNOSTICS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 15 EUROPE: COMPANION DIAGNOSTICS MARKET SHARE, BY REGION, 2020 (%)

FIGURE 16 ASIA-PACIFIC: COMPANION DIAGNOSTICS MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 17 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET SHARE, BY REGION, 2019 (%)

FIGURE 18 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 19 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN COMPANION DIAGNOSTIC MARKET

FIGURE 20 OEM PATIENT MONITORING MARKET AND GLOBAL COMPANION DIAGNOSTIC MARKET: COMPETITIVE LANDSCAPE

FIGURE 21 MAJOR PLAYERS SALES & OPERATING INCOME, 2020

FIGURE 22 MAJOR PLAYERS R&D EXPENDITURE, 2020

FIGURE 23 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 24 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS

FIGURE 25 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 26 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS

FIGURE 27 AGILENT TECHNOLOGIES, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 AGILENT TECHNOLOGIES, INC.: SWOT ANALYSIS

FIGURE 29 QIAGEN: FINANCIAL OVERVIEW

FIGURE 30 QIAGEN: SWOT ANALYSIS

FIGURE 31 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 BIOMÉRIEUX SA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 LEICA BIOSYSTEMS NUSSLOCH GMBH: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 34 ILLUMINA, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 MYRIAD GENETICS, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 36 MYRIAD GENETICS, INC.: SWOT ANALYSIS

FIGURE 37 ICON PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 38 GUARDANT HEALTH: FINANCIAL OVERVIEW SNAPSHOT.